The predicting role of serum tumor-specific growth factor for prognosis of esophageal squamous cell carcinoma.
Esophageal squamous cell carcinoma
Marker
Prognosis
Tumor-specific growth factor
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
06 Nov 2023
06 Nov 2023
Historique:
received:
24
06
2023
accepted:
02
11
2023
medline:
8
11
2023
pubmed:
7
11
2023
entrez:
6
11
2023
Statut:
epublish
Résumé
Tumor-specific growth factor (TSGF) is an immune-related factor that offers good performance in the clinical management of human cancers. However, the role of serum TSGF in esophageal squamous cell carcinoma (ESCC) has not been fully clarified. A total of 562 ESCC cases were collected in our study, with available information on preoperative serum levels of TSGF at diagnosis. Preoperative serum TSGF was detected using the rate method. We retrospectively analyzed its correlation with clinicopathological features of ESCC and survival. The cut-off value of serum TSGF was determined to be 60.5 U/mL by receiver operating characteristic (ROC) analysis. Serum TSGF was associated with gender (P < 0.001), tumor location (P = 0.022), tobacco use (P < 0.001), alcohol consumption (P < 0.001), lymph node involvement (P = 0.007), and TNM staging (P = 0.004). The survival analysis revealed that ESCC patients with high levels of serum TSGF had poorer prognosis than those with high TSGF (P = 0.006), especially for male ESCC cases (P = 0.001), under 60 year (P = 0.036), male middle location (P = 0.023), tobacco consumption (P = 0.004), G1 + G2 (P = 0.031), advanced T staging (P = 0.033), lymph node involvement (P = 0.003), TNM staging (P = 0.003). Univariate Cox regression analysis indicated that exposure to smoking and drinking, tumor grade, T staging, lymph node metastasis, TNM staging, and serum TSGF level were the prognosis-related factors of ESCC. Multivariate regression analysis revealed that smoking history, higher serum TSGF levels, and advanced T stage enhanced the risk of ESCC-related death. In brief, serum TSGF levels had in relation to malignant features of ESCC. It was positively correlated with survival but was identified as an independent risk factor for ESCC.
Identifiants
pubmed: 37932676
doi: 10.1186/s12885-023-11602-x
pii: 10.1186/s12885-023-11602-x
pmc: PMC10626642
doi:
Substances chimiques
Intercellular Signaling Peptides and Proteins
0
Biomarkers, Tumor
0
TSGF protein, human
0
Antigens, Neoplasm
0
Neoplasm Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1067Informations de copyright
© 2023. The Author(s).
Références
Am J Gastroenterol. 2014 Jun;109(6):822-7
pubmed: 24751582
Ann Palliat Med. 2020 Jul;9(4):2111-2117
pubmed: 32762227
Asian Pac J Cancer Prev. 2015;16(9):3867-70
pubmed: 25987051
J Gastroenterol Hepatol. 2020 Jun;35(6):1009-1015
pubmed: 31674067
Acta Pharm Sin B. 2021 Nov;11(11):3379-3392
pubmed: 34900524
Gastroenterology. 2018 Jan;154(2):360-373
pubmed: 28823862
J Cancer Res Ther. 2020;16(2):335-342
pubmed: 32474521
Am J Transl Res. 2021 Sep 15;13(9):10545-10553
pubmed: 34650725
Dis Markers. 2022 Sep 2;2022:3730679
pubmed: 36092957
Cell Biochem Biophys. 2015 Apr;71(3):1287-91
pubmed: 25486903
World J Gastroenterol. 2004 Jun 1;10(11):1675-7
pubmed: 15162550
Asian Pac J Cancer Prev. 2013;14(6):3877-80
pubmed: 23886200
J Int Med Res. 2009 May-Jun;37(3):878-83
pubmed: 19589273
J Cancer. 2021 Jan 1;12(4):1105-1114
pubmed: 33442408
Lin Chuang Er Bi Yan Hou Ke Za Zhi. 2005 Mar;19(5):201-2
pubmed: 15934283
Pathol Res Pract. 2017 Jul;213(7):842-847
pubmed: 28554754
Cell Physiol Biochem. 2018;47(1):26-38
pubmed: 29763905
Int J Mol Sci. 2014 May 28;15(6):9546-65
pubmed: 24879526
Asian Pac J Cancer Prev. 2013;14(7):4447-53
pubmed: 23992018
J Healthc Eng. 2021 Dec 10;2021:7380120
pubmed: 34925738
Ai Zheng. 2004 May;23(5):577-80
pubmed: 15142458
J Cancer Res Ther. 2016 Jan-Mar;12(1):117-20
pubmed: 27072222
PLoS One. 2011;6(10):e25347
pubmed: 22039411
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cancers (Basel). 2020 Oct 09;12(10):
pubmed: 33050257
Exp Ther Med. 2020 Aug;20(2):1822-1828
pubmed: 32742414